Ferguson Wellman Capital Management Inc. Sells 965 Shares of Pfizer Inc. $PFE

Ferguson Wellman Capital Management Inc. decreased its holdings in Pfizer Inc. (NYSE:PFE) by 2.4% in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 39,519 shares of the biopharmaceutical company’s stock after selling 965 shares during the quarter. Ferguson Wellman Capital Management Inc.’s holdings in Pfizer were worth $958,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in PFE. Brighton Jones LLC raised its stake in Pfizer by 1,282.4% in the 4th quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company’s stock worth $17,677,000 after acquiring an additional 618,117 shares during the last quarter. Revolve Wealth Partners LLC grew its position in Pfizer by 12.5% during the 4th quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company’s stock worth $498,000 after purchasing an additional 2,087 shares during the period. Vident Advisory LLC acquired a new stake in Pfizer during the 4th quarter worth about $248,000. Focus Partners Advisor Solutions LLC grew its position in Pfizer by 20.9% during the 4th quarter. Focus Partners Advisor Solutions LLC now owns 124,346 shares of the biopharmaceutical company’s stock worth $3,299,000 after purchasing an additional 21,519 shares during the period. Finally, BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp grew its position in Pfizer by 14.8% during the 4th quarter. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp now owns 1,085,110 shares of the biopharmaceutical company’s stock worth $28,788,000 after purchasing an additional 139,620 shares during the period. Institutional investors and hedge funds own 68.36% of the company’s stock.

Analysts Set New Price Targets

PFE has been the topic of a number of analyst reports. Bank of America raised their target price on Pfizer from $27.00 to $28.00 and gave the company a “neutral” rating in a research report on Wednesday, August 6th. Berenberg Bank dropped their target price on Pfizer from $28.00 to $25.00 and set a “hold” rating on the stock in a research report on Thursday, May 29th. Morgan Stanley raised their target price on Pfizer from $32.00 to $33.00 and gave the company an “equal weight” rating in a research report on Wednesday, August 6th. Finally, Citigroup raised their target price on Pfizer from $25.00 to $26.00 and gave the company a “neutral” rating in a research report on Wednesday, August 6th. Two investment analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, eleven have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $28.12.

Pfizer Trading Up 0.4%

PFE opened at $24.16 on Friday. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.16 and a quick ratio of 0.85. The company’s 50 day simple moving average is $24.67 and its two-hundred day simple moving average is $24.23. Pfizer Inc. has a 1-year low of $20.92 and a 1-year high of $30.43. The firm has a market capitalization of $137.33 billion, a price-to-earnings ratio of 12.85, a price-to-earnings-growth ratio of 0.85 and a beta of 0.55.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, topping analysts’ consensus estimates of $0.58 by $0.20. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The business had revenue of $14.65 billion for the quarter, compared to analyst estimates of $13.43 billion. During the same period last year, the company posted $0.60 EPS. The business’s revenue was up 10.3% on a year-over-year basis. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Analysts expect that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Tuesday, September 2nd. Shareholders of record on Friday, July 25th were paid a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 7.1%. The ex-dividend date of this dividend was Friday, July 25th. Pfizer’s dividend payout ratio (DPR) is 91.49%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.